product summary
Loading...
company name :
OriGene
product type :
antibody
product name :
NHLRC1 Mouse Monoclonal Antibody [Clone ID: N85/18]
catalog :
75-128
quantity :
100 µl
price :
598 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
N85/18
reactivity :
human
application :
western blot, immunocytochemistry
more info or order :
image
image 1 :

Immunoblot against extracts of COS cells transiently transfected with Flag-tagged Malin or untagged Kv2.1 plasmid probed with N85/18 TC supe (left) or rabbit polyclonal (right).
product information
SKU :
75-128
Category :
Antibodies
Sub-Category :
Primary Antibodies
Name :
NHLRC1 Mouse Monoclonal Antibody [Clone ID: N85/18]
Description :
NHLRC1 mouse monoclonal antibody, clone N85/18
Size :
100 µl
Price US :
598 USD
Delivery Time US :
3 Weeks
Symbol :
NHLRC1
Uniprot ID :
Q6VVB1
Datasheet URL :
https://neuromab.ucdavis.edu/datasheet/N85_18.pdf
Clonality :
Monoclonal
Clone Name :
N85/18
Host :
Mouse
Isotype :
IgG1
Applications :
IF, WB
Reactivity :
Human, Mouse, Rat
more info or order :
company information

OriGene
9620 Medical Center Dr., Suite 200
Rockville, MD 20850
Rockville, MD 20850
custsupport@origene.com
https://www.origene.com1-888-267-4436
headquarters: USA
OriGene Technologies, Inc. is a gene centric life sciences company dedicated to support biomedical scientists in gene functions and drug discovery. OriGene’s novel product line includes the world’s largest collections of cDNA clones (TrueClone and TrueORF), shRNA (HuSH-29), purified human recombinant proteins, high quality TrueMAB™ monoclonal antibodies to human proteins, 100,000 highly validated human tissues, and qPCR arrays. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. OriGene is a Luminex Certified Partner™ and offers multiplexed immunoassays and multiplexed assays for a broad range of biomarkers.
related products
browse more products
questions and comments